FDA approves Signos glucose monitoring for weight loss

Revolutionizing Weight Loss: FDA Approves First-Ever Glucose Monitoring System

The Food and Drug Administration (FDA) has given the green light to Signos, a startup that offers a groundbreaking glucose monitoring system designed specifically for weight loss. This innovative approach provides a new option for Americans to manage their weight, marking a significant shift in the way people can tackle obesity. Unlike current treatment options, such as popular drugs like GLP-1s and surgical interventions, which are typically limited to patients with a certain BMI or obesity, Signos’ system is available to anyone looking to lose weight.

Current obesity treatments, including medications like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, can be costly and difficult to access due to limited insurance coverage and constrained supply. In contrast, Signos’ system uses an AI platform and a continuous glucose monitor (CGM) from Dexcom to offer personalized, real-time data and lifestyle recommendations for weight management. This approach makes it more accessible and affordable for individuals seeking to lose weight, with plans starting at $139 for a three-month subscription.

A Solution for Every Weight Loss Journey

According to Sharam Fouladgar-Mercer, Signos’ co-founder and CEO, the system is designed to help individuals at any point in their weight loss journey, whether they need to lose five pounds or 100 pounds. With the average American having a significant amount of weight to lose, Signos aims to make a substantial impact on the obesity epidemic, which costs the U.S. healthcare system over $170 billion annually. The company hopes to make a “real big dent” in the curve, improving the lives of many Americans.

Signos’ system works by tracking glucose levels through a small sensor worn on the upper arm, which wirelessly sends data to the company’s app. Users can log their food intake, exercise levels, and other relevant information, allowing the AI platform to provide tailored recommendations for weight management. The system can be used in conjunction with other weight loss methods, such as GLP-1s or bariatric surgery, and can also help individuals maintain their weight loss after completing other treatments.

A New Era in Weight Management

While insurers currently do not cover Signos’ system for weight management, the company is working to change this. With plans significantly more affordable than traditional obesity treatments, Signos is poised to revolutionize the way people approach weight loss. By providing a comprehensive and personalized approach to weight management, Signos aims to help individuals understand how their bodies respond to specific foods and exercise patterns, making it easier to achieve and maintain a healthy weight in the long term.

With tens of thousands of people already having tried Signos’ system, the company is confident in its ability to make a significant impact on the obesity epidemic. By scaling up its CGM inventory and software capacity, Signos is prepared to handle a large influx of new users following the FDA approval. As the company continues to work with health insurance providers and employers to secure coverage, it is likely that Signos’ innovative approach to weight loss will become increasingly accessible to those who need it most.